<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658317</url>
  </required_header>
  <id_info>
    <org_study_id>RI in diabetic nephropathy</org_study_id>
    <nct_id>NCT03658317</nct_id>
  </id_info>
  <brief_title>Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy</brief_title>
  <official_title>Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      diabetic nephropathy is one of the leading causes of end stage renal disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus is one of the systemic diseases affecting the kidneys. Diabetic nephropathy&#xD;
      is a serious microvascular complication of diabetes mellitus. It is the most important cause&#xD;
      of death in type I diabetic patients, of whom 30%-40% eventually develop end-stage renal&#xD;
      failure and 40% of type II diabetics are at risk of developing diabetic nephropathy. So,&#xD;
      diagnosis of diabetic nephropathy is paramount for the survivability of the diabetic patients&#xD;
      not only because of the consequences of renal progression but also because of the strong&#xD;
      association with the risk of developing cardiovascular disease Diabetic nephropathy (DN) is&#xD;
      defined as persistent proteinuria greater than 500 mg/24 h, or albuminuria greater than 300&#xD;
      mg/24 h.&#xD;
&#xD;
      In the kidney, renal pathological changes leading to diabetic nephropathy are mainly&#xD;
      secondary to atherosclerosis of the intra and extra renal arteries together with&#xD;
      microangiopathy of the glomerular capillaries, afferent arterioles and efferent arteriole.&#xD;
&#xD;
      Doppler sonography may be a useful complementary test in the evaluation of DN, even in the&#xD;
      early stages. Early stage of vascular involvement seems, in fact, to be characterized by&#xD;
      functional alterations of endothelial control on vascular tone and wall interaction with&#xD;
      circulating cells. Renal Doppler assessment of RI is a reliable, non-invasive evaluation of&#xD;
      arterial function and is particularly useful for early diagnosis of vascular involvement.&#xD;
&#xD;
      Increasing evidence suggests that the intra-renal arterial RI, measured by Doppler&#xD;
      ultrasound, a well-established technique for the investigation of renal morphology and&#xD;
      hemodynamics, predicts the course of renal function in several conditions.&#xD;
&#xD;
      No standard, validated, cut-off to distinguish normal from high RI has been identified to&#xD;
      date. RI values between 0.75 and 0.85 have been associated with renal functional impairment&#xD;
      in patients with chronic kidney disease and stenosis of the renal artery, and they also&#xD;
      predict allograft dysfunction in kidney transplant recipients Little information is available&#xD;
      on the use of RI for the identification and prediction of DN in routine clinical practice. It&#xD;
      is yet unclear whether RI predicts DN in low-risk patients; also, the correlation between&#xD;
      increased intra-renal RI and altered renal hemodynamics remains unclear independent of&#xD;
      albuminuria, as also the most appropriate cut-off value The renal arterial resistive index&#xD;
      (RI) is a sonographic index to assess for renal arterial disease. It is measured as RI =&#xD;
      (peak systolic velocity - end diastolic velocity ) / peak systolic velocity Measured at&#xD;
      arcuate arteries (at the corticomedullary junction) or interlobar arteries (adjacent to&#xD;
      medullary pyramids) intrarenal resistive index (RI) has been reported to be increased in&#xD;
      hypertensive subjects with microalbuminuria and limited data is present for diabetic&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal resistive index</measure>
    <time_frame>once(1day)</time_frame>
    <description>calculated by the renal dupplex</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stage of diabetic nephropathy</measure>
    <time_frame>once(1day)</time_frame>
    <description>assessed by the proteinuria level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>cases</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>renal arterial resistive index</intervention_name>
    <description>done by dupplex on renal arteries</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>uric acid level</intervention_name>
    <description>serum sample for doing the test</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum urea and creatinine</intervention_name>
    <description>serum samples for doing the test</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>24 hours urinary proteins</intervention_name>
    <description>urine collected over 24 hours for doing the test</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>lipogram</intervention_name>
    <description>serum sample for doing the test</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
    <other_name>lipid profile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HbA1c level</intervention_name>
    <description>serum sample for doing the test</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>urine analysis</intervention_name>
    <description>urine sample for doing the test</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>abdominal ultrasonography</intervention_name>
    <description>done by the ultrasonography device</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients either type I or type II diabetes mellitus with or without any&#xD;
             clinical evidence of diabetic nephropathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disease affecting the cardiovascular system as vasculitis and hypertension&#xD;
             Patients with ESRD due to diabetic nephropathy on regular dialysis Patients with&#xD;
             nephrolithiasis Patients having any type of glomerulonephritis Patients with renal&#xD;
             artery stenosis Renal transplantation recipients patients suffering from polycystic&#xD;
             kidney disease or any other structural renal disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>muhammed A sobh, professor</last_name>
    <phone>+201069272662</phone>
    <email>muhammed.sobh@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>marwa k khairallah, MD</last_name>
    <phone>+201147536066</phone>
    <email>marwa.kamal82@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Steinke JM, Mauer M; International Diabetic Nephropathy Study Group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev. 2008 Aug;5 Suppl 4:958-63. Review.</citation>
    <PMID>18806710</PMID>
  </reference>
  <reference>
    <citation>Tublin ME, Bude RO, Platt JF. Review. The resistive index in renal Doppler sonography: where do we stand? AJR Am J Roentgenol. 2003 Apr;180(4):885-92. Review.</citation>
    <PMID>12646425</PMID>
  </reference>
  <reference>
    <citation>Youssef DM, Fawzy FM. Value of renal resistive index as an early marker of diabetic nephropathy in children with type-1 diabetes mellitus. Saudi J Kidney Dis Transpl. 2012 Sep;23(5):985-92. doi: 10.4103/1319-2442.100880.</citation>
    <PMID>22982911</PMID>
  </reference>
  <results_reference>
    <citation>Afsar B, Elsurer R. Increased renal resistive index in type 2 diabetes: Clinical relevance, mechanisms and future directions. Diabetes Metab Syndr. 2017 Oct - Dec;11(4):291-296. doi: 10.1016/j.dsx.2016.08.019. Epub 2016 Aug 30. Review.</citation>
    <PMID>27594114</PMID>
  </results_reference>
  <results_reference>
    <citation>Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005 Jan;28(1):164-76. Review.</citation>
    <PMID>15616252</PMID>
  </results_reference>
  <results_reference>
    <citation>Masulli M, Mancini M, Liuzzi R, Daniele S, Mainenti PP, Vergara E, Genovese S, Salvatore M, Vaccaro O. Measurement of the intrarenal arterial resistance index for the identification and prediction of diabetic nephropathy. Nutr Metab Cardiovasc Dis. 2009 Jun;19(5):358-64. doi: 10.1016/j.numecd.2008.07.003. Epub 2008 Sep 20.</citation>
    <PMID>18805683</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozmen ND, Mousa U, Aydin Y, Deren T, Unlu EB. Association of the renal resistive index with microvascular complications in type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2015 Feb;123(2):112-7. doi: 10.1055/s-0034-1390448. Epub 2014 Oct 24.</citation>
    <PMID>25343266</PMID>
  </results_reference>
  <results_reference>
    <citation>Shirin M, Sharif MM, Gurung A, Datta A. Resistive Index of Intrarenal Artery in Evaluation of Diabetic Nephropathy. Bangladesh Med Res Counc Bull. 2015 Dec;41(3):125-130.</citation>
    <PMID>29870167</PMID>
  </results_reference>
  <results_reference>
    <citation>Said SM, Nasr SH. Silent diabetic nephropathy. Kidney Int. 2016 Jul;90(1):24-6. doi: 10.1016/j.kint.2016.02.042.</citation>
    <PMID>27312444</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 1, 2018</study_first_submitted>
  <study_first_submitted_qc>September 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>radwa awad abd elhafiz ibrahim</investigator_full_name>
    <investigator_title>doctor ,assisstant lecturer,principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

